Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases

Clin Gastroenterol Hepatol. 2021 Feb;19(2):394-396.e5. doi: 10.1016/j.cgh.2020.10.010. Epub 2020 Oct 12.


The coronavirus disease 2019 (COVID-19) pandemic caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents most often with mild clinical symptoms, but the severe forms are of major concern.1 SARS-CoV-2 enters human cells via the angiotensin-converting enzyme 2 receptor, expressed on epithelial and endothelial cells.2 Because the highest angiotensin-converting enzyme 2 expression is in the terminal ileum and colon, and up-regulated further during inflammation, and many COVID-19 patients experience gastrointestinal symptoms, longitudinal data are necessary to determine whether inflammatory bowel disease (IBD) patients are at risk for severe or complicated COVID-19. A recent analysis in IBD patients from the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) registry showed older age, steroid medication, and comorbidities as risk factors for severe evolution, and the same study showed that the 29 IBD patients younger than age 20 had only mild disease courses.3 This report describes the disease course of COVID-19 in an expanded sample of pediatric IBD patients from 2 international databases.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Ambulatory Care
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • COVID-19 / epidemiology
  • COVID-19 / physiopathology*
  • COVID-19 / therapy
  • Child
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / epidemiology
  • Comorbidity
  • Crohn Disease / drug therapy*
  • Crohn Disease / epidemiology
  • Female
  • Hospitalization
  • Humans
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / epidemiology
  • Male
  • Mesalamine / therapeutic use
  • SARS-CoV-2
  • Sulfasalazine / therapeutic use
  • Systemic Inflammatory Response Syndrome / epidemiology
  • Systemic Inflammatory Response Syndrome / physiopathology*
  • Systemic Inflammatory Response Syndrome / therapy
  • Tumor Necrosis Factor Inhibitors / therapeutic use*


  • Anti-Inflammatory Agents, Non-Steroidal
  • Tumor Necrosis Factor Inhibitors
  • Sulfasalazine
  • Mesalamine

Supplementary concepts

  • Pediatric Crohn's disease
  • Pediatric ulcerative colitis
  • pediatric multisystem inflammatory disease, COVID-19 related